|
| N-(4-methylphenyl)-2-[(5-nitro-1H-benzimidazol-2-yl)sulfanyl]acetamide |
|
Pseudomonas |
Biofilm |
Preclinical (in vitro) |
Starkey M, et al. 2014. PLoS Pathog |
|
| N-[3-(2-amino-1H-imidazol-5-yl)phenyl]heptanamide;hydrochloride |
|
Pseudomonas |
Biofilm |
Preclinical (in vitro) |
Bunders CA, et al. 2010. Bioorg Med Chem Lett |
|
| Heptanoic acid [4-(2-amino-3H-imidazol-4-yl)phenyl]amide hydrochloride |
|
Pseudomonas |
Biofilm |
Preclinical (in vitro) |
Bunders CA, et al. 2010. Bioorg Med Chem Lett |
|
| Fenbendazole |
|
Salmonella |
Invasion |
Preclinical (in vitro) |
Ridge Y, et al. 2018. J Appl Microbiol |
|
| N-[2-[4-(benzimidazol-1-yl)anilino]-2-oxoethyl]-3-chloro-1-benzothiophene-2-carboxamide |
|
Salmonella
Yersinia |
TTSS (SPI-1 encode)
TTSS (Type III secretion system) |
Preclinical (in vitro)
Preclinical (in vivo) |
Boonyom R, et al. 2022. J Genet Eng Biotechnol
Swietnicki W, et al. 2011. PLoS One |
|
| 5-Chloro-2-phenoxymethyl-1H-benzoimidazole |
|
Shigella |
VirF |
Preclinical (in vitro) |
Emanuele AA, et al. 2014. J Antibiot (Tokyo); Emanuele AA, et al. 2015. PLoS One |
|
| 3-(5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)propan-1-ol |
|
Vibrio |
Post-translational modification |
Preclinical (in vitro) |
Wang G, et al. 2022. ChemMedChem |
|
| Isonaamine A |
|
Vibrio |
Biofilm |
Preclinical (in vitro) |
Mai T, et al. 2015. Lett Appl Microbiol |
|
| Isonaamine D |
|
Vibrio |
Biofilm |
Preclinical (in vitro) |
Mai T, et al. 2015. Lett Appl Microbiol |
|
Benzimidazole 2
(internal name in literature) |
|
Vibrio |
Post-translational modification |
Preclinical (in vitro) |
Wang G, et al. 2022. ChemMedChem |
|
| | | |
